Evercore ISI analyst Liisa Bayko initiated coverage of Caribou Biosciences with an Outperform rating and $13 price target. Caribou shares are trading below cash and are down 40% year-to-date, mostly due to biotech market conditions and the cell therapy field facing high competition, the analyst tells investors. Against this backdrop, Caribou “stands apart with a best in class offering,” says the firm, which expects two important catalysts could lift shares in the next 12 months. Namely, Evercore points to FDA feedback on a regulatory strategy, including a potential pivotal trial for its lead program CB-010 by year-end, as well as added data from the CB-010 program in the first half of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRBU:
- Caribou Biosciences announces FDA clearance of IND application for CB-012
- Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Caribou Biosciences appoints Zawadzki as Chief People Officer
- Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
- Caribou Biosciences price target lowered to $30 from $37 at Citi